a simple calc...
Lets say.. 20,000 CF bronhitol users in AU/EU by end of FY13 (assumption: EMA approval granted).
Price: $10,000 AUD (conservative estimate)
Total revenue: 20,000 x $10,000 = 200M
operating costs: $60M (my best guess)
Total earnings = 200M - 60M = 140M
EPS = 140M / 220M (no. shares on issues) = 63c per share
The average PE for biotech (see CSL / COH) is 20 however given the relative size of PXS - lets say PE of 13 is warranted.
Therefore, potential PE by end of 2012 is: 63c x 13 = $8.19 (300% increase from current levels).
This excludes any upside from FDA CF approval and other uses for bronhitol.
Thoughts?
Feel free to add in your working calculations if your views differ from mine.
- Forums
- ASX - By Stock
- SNT
- what is pxs worth?
what is pxs worth?
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.1¢ |
Change
-0.002(6.06%) |
Mkt cap ! $40.00M |
Open | High | Low | Value | Volume |
3.3¢ | 3.3¢ | 3.1¢ | $10.37K | 325.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 354657 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.3¢ | 210596 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 354657 | 0.031 |
8 | 1359343 | 0.030 |
5 | 840000 | 0.029 |
4 | 1855000 | 0.028 |
1 | 60000 | 0.026 |
Price($) | Vol. | No. |
---|---|---|
0.033 | 210596 | 1 |
0.034 | 661268 | 3 |
0.035 | 316000 | 2 |
0.036 | 343537 | 2 |
0.039 | 400000 | 1 |
Last trade - 15.43pm 18/09/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |